Cargando…
5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes
Colorectal cancer (CRC) is a public health problem. It is the third most common cancer in the world, with nearly 1.8 million new cases diagnosed in 2018. The only curative treatment is surgery, especially for early tumor stages. When there is locoregional or distant invasion, chemotherapy can be int...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469786/ https://www.ncbi.nlm.nih.gov/pubmed/32536012 http://dx.doi.org/10.1111/cas.14532 |
_version_ | 1783578465285439488 |
---|---|
author | Blondy, Sabrina David, Valentin Verdier, Mireille Mathonnet, Muriel Perraud, Aurélie Christou, Niki |
author_facet | Blondy, Sabrina David, Valentin Verdier, Mireille Mathonnet, Muriel Perraud, Aurélie Christou, Niki |
author_sort | Blondy, Sabrina |
collection | PubMed |
description | Colorectal cancer (CRC) is a public health problem. It is the third most common cancer in the world, with nearly 1.8 million new cases diagnosed in 2018. The only curative treatment is surgery, especially for early tumor stages. When there is locoregional or distant invasion, chemotherapy can be introduced, in particular 5‐fluorouracil (5‐FU). However, the disease can become tolerant to these pharmaceutical treatments: resistance emerges, leading to early tumor recurrence. Different mechanisms can explain this 5‐FU resistance. Some are disease‐specific, whereas others, such as drug efflux, are evolutionarily conserved. These mechanisms are numerous and complex and can occur simultaneously in cells exposed to 5‐FU. In this review, we construct a global outline of different mechanisms from disruption of 5‐FU‐metabolic enzymes and classic cellular processes (apoptosis, autophagy, glucose metabolism, oxidative stress, respiration, and cell cycle perturbation) to drug transporters and epithelial‐mesenchymal transition induction. Particular interest is directed to tumor microenvironment function as well as epigenetic alterations and miRNA dysregulation, which are the more promising processes that will be the subject of much research in the future. |
format | Online Article Text |
id | pubmed-7469786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74697862020-09-09 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes Blondy, Sabrina David, Valentin Verdier, Mireille Mathonnet, Muriel Perraud, Aurélie Christou, Niki Cancer Sci Review Articles Colorectal cancer (CRC) is a public health problem. It is the third most common cancer in the world, with nearly 1.8 million new cases diagnosed in 2018. The only curative treatment is surgery, especially for early tumor stages. When there is locoregional or distant invasion, chemotherapy can be introduced, in particular 5‐fluorouracil (5‐FU). However, the disease can become tolerant to these pharmaceutical treatments: resistance emerges, leading to early tumor recurrence. Different mechanisms can explain this 5‐FU resistance. Some are disease‐specific, whereas others, such as drug efflux, are evolutionarily conserved. These mechanisms are numerous and complex and can occur simultaneously in cells exposed to 5‐FU. In this review, we construct a global outline of different mechanisms from disruption of 5‐FU‐metabolic enzymes and classic cellular processes (apoptosis, autophagy, glucose metabolism, oxidative stress, respiration, and cell cycle perturbation) to drug transporters and epithelial‐mesenchymal transition induction. Particular interest is directed to tumor microenvironment function as well as epigenetic alterations and miRNA dysregulation, which are the more promising processes that will be the subject of much research in the future. John Wiley and Sons Inc. 2020-08-13 2020-09 /pmc/articles/PMC7469786/ /pubmed/32536012 http://dx.doi.org/10.1111/cas.14532 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Blondy, Sabrina David, Valentin Verdier, Mireille Mathonnet, Muriel Perraud, Aurélie Christou, Niki 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes |
title | 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes |
title_full | 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes |
title_fullStr | 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes |
title_full_unstemmed | 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes |
title_short | 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes |
title_sort | 5‐fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469786/ https://www.ncbi.nlm.nih.gov/pubmed/32536012 http://dx.doi.org/10.1111/cas.14532 |
work_keys_str_mv | AT blondysabrina 5fluorouracilresistancemechanismsincolorectalcancerfromclassicalpathwaystopromisingprocesses AT davidvalentin 5fluorouracilresistancemechanismsincolorectalcancerfromclassicalpathwaystopromisingprocesses AT verdiermireille 5fluorouracilresistancemechanismsincolorectalcancerfromclassicalpathwaystopromisingprocesses AT mathonnetmuriel 5fluorouracilresistancemechanismsincolorectalcancerfromclassicalpathwaystopromisingprocesses AT perraudaurelie 5fluorouracilresistancemechanismsincolorectalcancerfromclassicalpathwaystopromisingprocesses AT christouniki 5fluorouracilresistancemechanismsincolorectalcancerfromclassicalpathwaystopromisingprocesses |